Abstracts tagged "Cardiovascular"

Abstract Number: 0487 • ACR Convergence 2024
The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose Felix Restrepo Suarez¹, Carlos Lorenzo¹, Inmaculada Del rincon² and Agustin Escalante¹, ¹UT Health San Antonio, San Antonio, TX, ²UT Health San Antonio, San Antonio
Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…
Abstract Number: 0841 • ACR Convergence 2024
Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Michael Parides¹, Danieli Andrade², Diana Paredes-Ruiz³, Maria Tektonidou⁴, Vittorio Pengo⁵, Savino Sciascia⁶, Cecilia Nalli⁷, Guilherme Ramires de Jesús⁸, Paul Fortin⁹, Maria Efthymiou¹⁰, H Michael Belmont¹¹, Michelle Petri¹², Ricard Cervera¹³, Leslie Skeith¹⁴, TATSUYA ATSUMI¹⁵, Chary Lopez-Pedrera¹⁶, Yu Zuo¹⁷, David Branch¹⁸, Rohan Willis¹⁹, Nina Kello²⁰, Zhuoli Zhang²¹, Esther Rodriguez-Almaraz²², Bahar Artim Esen²³, Jose Pardos-Gea²⁴, Guillermo Pons-Estel²⁵, Giulia Pazzola²⁶, Hui Shi¹⁷, Ali Duarte-Garcia²⁷, Medha Barbhaiya¹, Cécile Yelnik²⁸, Pierluigi Meroni²⁹, Robert Roubey³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Jacob Rand³³ and Doruk Erkan¹, and on behalf of APS ACTION, ¹Hospital for Special Surgery, New York, NY, ²University of São Paulo, São Paulo, SP, Brazil, ³Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁶University of Turin, Torino, Turin, Italy, ⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ⁹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁰University College London, London, United Kingdom, ¹¹NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴University of Calgary, Calgary, ON, Canada, ¹⁵Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁹University of Texas Medical Branch, Galveston, TX, ²⁰Northwell Health, Brooklyn, NY, ²¹Peking University First Hospital, Beijing, China, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁴Vall d'Hebron University Hospital, Barcelona, Spain, ²⁵CREAR, Rosario, Argentina, ²⁶Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²⁷Mayo Clinic, Rochester, MN, ²⁸lille university, Lille, France, ²⁹IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³Weill Cornell Medical Center, Bronx, NY
Background/Purpose: There is a lack of high-quality data to inform risk-stratified long-term thrombosis prevention strategies in patients with persistently positive antiphospholipid antibodies (aPL). The APS…
Abstract Number: 1133 • ACR Convergence 2024
Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators
Maria F. Elizondo-Benitez¹, Iris Jazmín Colunga Pedraza², jose Ramon Azpiri-Lopez³, Dionicio Galarza-Delgado⁴, Jesus Cardenas-de la Garza⁵, Rosa Icela Arvizu-Rivera², Andrea Guajardo Aldaco² and Valeria Gonzalez-Gonzalez⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory, and immune-mediated disease that affects up to 30% of psoriasis (PsO) patients. Nail psoriasis affects 80% of…
Abstract Number: 1567 • ACR Convergence 2024
Systemic Sclerosis Is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Perfusion and Increased Fibrosis
Chin Yit Soo¹, Nicholas Jex², Stefano Di Donato³, Lucy Elizabeth Thornton⁴, Vishal Kakkar⁵, Riccardo Bixio⁶, Raluca Tomoaia¹, Thomas Anderton², May Lwin², Christel Kamani², Amrit Chowdhary², Henry Procter¹, Sharmaine Thirunavukarasu¹, Sindhoora Kotha², Marilena Giannoudi², Eylem Levelt², Sven Plein¹, Francesco Delgado⁶ and Lesley-Anne Bissell⁷, ¹Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, England, United Kingdom, ²Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, ³1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ⁴1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, ⁵University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, ⁷Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Primary cardiac involvement in systemic sclerosis (SSc) is heterogenous, poorly defined and associated with significant cardiac morbidity and mortality. The underlying mechanism is not…
Abstract Number: 2038 • ACR Convergence 2024
Nationwide Analysis of Adult Hospitalizations with Rheumatologic Conditions and Spontaneous Coronary Artery Dissection
Maria Romero Noboa¹, Husam El Sharu², Diego Cornejo³, Rafaella Litvin⁴ and Almurtada Razok⁴, ¹University of Alabama at Birmingham, Chicago, IL, ²East Carolina University, Greenville, NC, ³John H Stroger Hospital of Cook County, Chicago, ⁴John H Stroger Jr Hospital of Cook County, Chicago, IL
Background/Purpose: Rheumatic diseases have a higher risk of cardiovascular events, particularly those related to atherothrombosis which represents the leading cause of premature mortality in most of…
Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
Abstract Number: 0147 • ACR Convergence 2024
Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Mary Jeffway¹, Feng Liu¹, Nancy Shadick¹, Michael Weinblatt², Brittany Weber³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ³Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: General population-based cardiovascular (CV) risk estimators are known to underestimate CV risk in RA. High-sensitivity cardiac troponin T (hs-cTnT), typically measured during a work-up…
Abstract Number: 0497 • ACR Convergence 2024
Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
Adrián Quevedo-Rodríguez¹, Marta Hernández-Díaz², Dara Rodríguez-González2², Fuensanta Gomez-Bernal³, Juan Carlos Quevedo-Abeledo⁴, Agustín F González-Rivero², Elena González López⁵, gonzalo Ocejo-Viñals⁵, Miguel Angel Gonzalez-Gay⁶ and ivan Ferraz-Amaro⁷, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁵Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Carotid subclinical atherosclerosis is independently associated with incident…
Abstract Number: 0849 • ACR Convergence 2024
Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Iñigo Hernández-Rodríguez⁴, Susana Romero Yuste⁵, Eugenio De Miguel⁶, Eva Galindez-Agirregoikoa⁷, ivan Ferraz-Amaro⁸, Julio Sánchez-Martín⁹, Patricia Moya Albarado¹⁰, Cristina Campos Fernández¹¹, Fernando Lopez-Gutierrez¹², Santos Castañeda¹³ and Ricardo Blanco-Alonso¹⁴, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁵Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Hospital de San Pau, Barcelona, Spain, ¹¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant Cell Arteritis (GCA) was initially described involving mainly the extracranial branches of the carotid arteries. However, GCA also may involve the aorta (GCA-aortitis)…
Abstract Number: 1188 • ACR Convergence 2024
High Risk of Stroke in Men with Joint Prosthesis Due to Osteoarthritis: The Prospective STRAMBO Study
MAXIME AUROUX¹, PAWEL SZULC² and ROLAND CHAPURLAT¹, ¹Hospices Civls de Lyon, LYON, Rhone-Alpes, France, ²INSERM U1033, LYON, Rhone-Alpes, France
Background/Purpose: Osteoarthritis (OA) and cardiovascular disease share risk factors. The impact of OA on cardiovascular and especially cerebrovascular outcomes is still debated. Our aim was to…
Abstract Number: 1579 • ACR Convergence 2024
Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis
Omar Mourad¹, Saif Abu Baker¹, Georges Khattar², Jennifer Jdaidani³, Khalil El-Gharib³ and Ahmad Mustafa³, ¹Staten Island University Hospital- Northwell Health, Staten Island, NY, ²Staten Island University Hospital, Staten Island, NY, ³Staten Island University Hospital- Northwell Health, Staten Island
Background/Purpose: Systemic sclerosis (SS) is a complex autoimmune rheumatic disease characterized by immune-mediated activation of both innate and adaptive immunity. Pulmonary involvement, specifically pulmonary arterial…
Abstract Number: 2213 • ACR Convergence 2024
Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis
Vanshika Sabharwal, and Dr Ashit syngle and Dr Inderjeet Verma, MMDU, Mullana, Ambala India and Healing Touch city clinic, Chandigarh, India, Chandigarh, Chandigarh, India
Background/Purpose: RA is a chronic inflammatory disease associated with an excessive premature cardiovascular morbidity and mortality. Endothelial dysfunction is a significant contributor to CVD in…
Abstract Number: 2508 • ACR Convergence 2024
The Impact of Lipid Profile Parameters on the Incidence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients: A Single-arm Meta-Analysis
Nouman Shafique¹, Ali Raza Khan², Abdul Qadeer², zaigham Shaukat² and Rabia Iqbal², ¹AdventHealth Orlando, Orlando, FL, ²Nishtar Medical University, Multan, Punjab, Pakistan
Background/Purpose: Cardiovascular diseases (CVD) are a significant cause of morbidity and mortality among patients with rheumatoid arthritis (RA), accounting for nearly 40% of their mortality.…
Abstract Number: 0156 • ACR Convergence 2024
Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults
Anurag Goel¹, Joshua Tanzer² and Vinit Gilvaz³, ¹The Warren Alpert Medical School of Brown University, Providence, RI, ²Lifespan Biostatistics, Epidemiology, Research Design, and Informatics Core, Providence, RI, ³The Warren Alpert Medical School of Brown University, East Providence, RI
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated…
Abstract Number: 0503 • ACR Convergence 2024
Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Patrick-Pascal Strunz¹, Linus Maximilian Risser², Matthias Englbrecht³, Torsten Witte⁴, Matthias Froehlich⁵, Marc Schmalzing⁶, Michael Gernert⁷, Peter Bartz-Bazzanella⁸, Sebastian Hueper⁹, Cay von Der Decken¹⁰, Georg Gauler¹¹, Susanna Spaethling-Mestekemper¹², Christoph Kuhn¹³, Kirsten Karberg¹⁴, Wolfgang Vorbrueggen¹⁵, Martin Welcker¹⁶ and Stefan Kleinert¹⁷, ¹University hospital of Wuerzburg, Wuerzburg, Germany, ²Hannover Medical School, Hannover, Germany, ³Freelance Healthcare Data Scientist, Eckental, ⁴Dept of Immunology and Rheumatology, Hannover, Germany, ⁵Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ⁶University Hospital Wuerzburg, Würzburg, Germany, ⁷Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ⁸Rhein-Maas Klinikum, Wuerselen, Germany, ⁹Praxis für Rheumatologie und Osteologie, Hildesheim, Germany, ¹⁰Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, ¹¹rheumapraxis, Osnabrück, Germany, ¹²Rheumapraxis Muenchen, Muenchen, Germany, ¹³Praxis für Rheumatologie, Karlsruhe, Germany, ¹⁴Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, ¹⁵RheumaDatenRhePort GbR, Wuerselen, Germany, ¹⁶Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ¹⁷Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence prescription patterns for drugs used…

« Previous Page
1
…
3
4
5
6
7
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].